Approximately 65% of Women in the United States Are Using Contraceptives
Almost two-thirds of U.S. women aged 15 to 49 years were currently using contraception in 2015 to 2017.
Almost two-thirds of U.S. women aged 15 to 49 years were currently using contraception in 2015 to 2017.
Phase 3 trial results assessing the intrauterine system, Liletta (levonorgestrel 52 mg), found that it had >99% efficacy in preventing pregnancy for up to 5 years; the products current Food and Drug Administration indication.
One-third of the women enrolled in Michigan’s Medicaid expansion program reported improved access to birth control and family planning services.
There is a reduction in ovarian cancer risk associated with use of contemporary combined hormonal contraceptives.
Healthy nonmenopausal women taking oral contraceptives exhibited biomarkers for drug-induced torsade de pointes.
The algorithm was designed to account for sperm survival, variation in cycle length, ovulation day, temperature fluctuations and the length of the follicular and luteal phases of the menstrual cycle.
The safety and efficacy of Annovera was evaluated in 3 open-label clinical trials involving healthy women (ages 18 to 40).
Current oral contraceptive products contain lower doses of estrogen than those used in the past, prompting reconsideration of risks and benefits.
Researchers examined unplanned pregnancies and contraceptive use among HIV-positive women in a cross-sectional study.
Investigators examined the effect of progestin-only contraceptive on cardiometabolic outcomes, including stroke, MI, hypertension, diabetes, and VTE.